HCI (HCI) Company Overview

HCI Group shows stable top-line performance and liquidity despite the high-risk Florida P&C insurance market, making it a solid investment candidate. The company's cautious expansion strategy and strong balance sheet, with over $500M in cash, ensure it can cover operations and claims efficiently. Despite impressive performance, HCI's stock appears overvalued with a 24% downside risk based on P/B and DCF models, suggesting a hold recommendation.

TAMPA, Fla., Feb. 04, 2025 (GLOBE NEWSWIRE) -- The board of directors of HCI Group, Inc. (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid March 21, 2025 to shareholders of record at the close of business February 21, 2025.

On the most recent trading day, HCI Group (HCI) closed at $121.84, which is a decrease of 0.07% compared to its last closing price.

HCI Group (HCI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

TAMPA, Fla., Jan. 29, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, will hold a conference call on Thursday, February 27, 2025, at 4:45 p.m. Eastern time to discuss results for the fourth quarter and year ended December 31, 2024. Financial results will be issued in a press release the same day after the close of the market.

The latest trading day saw HCI Group (HCI) settling at $121.75, representing a +0.29% change from its previous close.

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals' KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 This six-year agreement complements and strengthens Emergent's mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education.

TAMPA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, has announced that its 4.75% Convertible Senior Notes Due 2042 became convertible by all Holders on January 1, 2025.

HCI Group, Inc. (NYSE:HCI ) Q3 2024 Earnings Conference Call November 7, 2024 4:45 PM ET Company Participants Matt Glover - Senior Managing Director-Gateway Investor Relations Karin Coleman - Chief Operating Officer Mark Harmsworth - Chief Financial Officer Paresh Patel - Chief Executive Officer Conference Call Participants Matt Carletti - Citizens JMP Mark Hughes - Truist Casey Alexander - Compass Point Michael Phillips - Oppenheimer Operator Good afternoon, and welcome to HCI Group's Third Quarter 2024 Earnings Call. My name is Paul, and I will be your conference operator.